FilingReader Intelligence
Photocure partner advances Cevira to second regulatory review
August 4, 2025 at 02:01 PM UTC•By FilingReader AI
Photocure ASA announced that partner Asieris Pharmaceuticals has advanced Cevira to the second round of technical review for its New Drug Application.
The photodynamic drug-device combination product treats high-grade squamous intraepithelial lesions non-surgically. Photocure out-licensed global rights to Asieris in 2019.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
OSL:PHO•Oslo Stock Exchange
News Alerts
Get instant email alerts when Photocure ASA publishes news
Free account required • Unsubscribe anytime